Inducible cyclooxygenase released prostaglandin E2 modulates the severity of infection caused by Streptococcus pyogenes

Journal of Immunology

Volumn 185, Issue 4, 2010, Pages 2372-2381

  Goldmann, Oliver ^a   Hertzén, Erika ^b   Hecht, Alexander ^a   Schmidt, Heike ^a   Lehne, Sabine ^a   Norrby Teglund, Anna ^b   Medina, Eva ^a  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; 7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; BUTAPROST; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOOXYGENASE 2; FORSKOLIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2; ROLIPRAN; SULPROSTONE; UNCLASSIFIED DRUG; VAPIPROST; 6-ISOPROPOXY-9-OXOXANTHENE-2-CARBOXYLIC ACID; N-(2-CYCLOHEXYLOXY-4-NITROPHENYL)METHANESULFONAMIDE; NITROBENZENE DERIVATIVE; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; REACTIVE OXYGEN METABOLITE; SULFONAMIDE; XANTHONE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; CELL KILLING; CELLULITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME RELEASE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; MACROPHAGE; NECROTIZING FASCIITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; TOXIC SHOCK SYNDROME; ANIMAL; C3H MOUSE; CELL CULTURE; CYTOLOGY; DRUG ANTAGONISM; GENETICS; HOSPITALIZATION; HOST PATHOGEN INTERACTION; IMMUNOHISTOCHEMISTRY; METABOLISM; MICROBIOLOGY; MOUSE; MOUSE MUTANT; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CELLS, CULTURED; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; FEMALE; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MICE; MICE, INBRED C3H; MICE, KNOCKOUT; NITROBENZENES; PROSTAGLANDIN ANTAGONISTS; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; SULFONAMIDES; XANTHONES;

EID: 77956926627     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000838     Document Type: Article

References (48)

1. Jaggi, P., and S. T. Shulman. 2006. Group A streptococcal infections. Pediatr. Rev. 27: 99-105.
2. Abdeltawab, N. F., R. K. Aziz, R. Kansal, S. L. Rowe, Y. Su, L. Gardner, C. Brannen, M. M. Nooh, R. R. Attia, H. A. Abdelsamed, et al. 2008. An unbiased systems genetics approach to mapping genetic loci modulating susceptibility to severe streptococcal sepsis. PLoS Pathog. 4: e1000042.
3. Harris, S. G., J. Padilla, L. Koumas, D. Ray, and R. P. Phipps. 2002. Prostaglandins as modulators of immunity. Trends Immunol. 23: 144-150.
4. 2 is a potent inhibitor of human interleukin 12 production. J. Exp. Med. 181: 775-779.
5. 4 receptor. J. Biol. Chem. 277: 44147-44154.
6. Nagamachi, M., D. Sakata, K. Kabashima, T. Furuyashiki, T. Murata, E. Segi- Nishida, K. Soontrapa, T. Matsuoka, Y. Miyachi, and S. Narumiya. 2007. Facilitation of Th1-mediated immune response by prostaglandin E receptor EP1. J. Exp. Med. 204: 2865-2874.
7. 2 promotes the survival of bone marrow-derived dendritic cells. J. Immunol. 173: 6955-6964.
8. 4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat. Med. 9: 744-749.
9. 2 alters the IL-12/IL-23 balance and promotes differentiation of Th17 cells. J. Immunol. 181: 721-735.
10. Fink, M. P. 2001. Prostaglandins and sepsis: still a fascinating topic despite almost 40 years of research. Am. J. Physiol. Lung Cell. Mol. Physiol. 281: L534-L536.
11. Shimizu, T. 2009. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu. Rev. Pharmacol. Toxicol. 49: 123-150.
12. Simmons, D. L., R. M. Botting, and T. Hla. 2004. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 56: 387-437.
13. Dubois, R. N., S. B. Abramson, L. Crofford, R. A. Gupta, L. S. Simon, L. B. Van De Putte, and P. E. Lipsky. 1998. Cyclooxygenase in biology and disease. FASEB J. 12: 1063-1073.
14. Richardson, J. Y., M. G. Ottolini, L. Pletneva, M. Boukhvalova, S. Zhang, S. N. Vogel, G. A. Prince, and J. C. Blanco. 2005. Respiratory syncytial virus (RSV) infection induces cyclooxygenase 2: a potential target for RSV therapy. J. Immunol. 174: 4356-4364.
15. Sadikot, R. T., H. Zeng, A. C. Azim, M. Joo, S. K. Dey, R. M. Breyer, R. S. Peebles, T. S. Blackwell, and J. W. Christman. 2007. Bacterial clearance of Pseudomonas aeruginosa is enhanced by the inhibition of COX-2. Eur. J. Immunol. 37: 1001-1009.
16. Ball, H. J., H. G. MacDougall, I. S. McGregor, and N. H. Hunt. 2004. Cyclooxygenase-2 in the pathogenesis of murine cerebral malaria. J. Infect. Dis. 189: 751-758.
17. Li, G. Q., H. H. Xia, M. H. Chen, Q. Gu, J. D. Wang, J. Z. Peng, A. O. Chan, C. H. Cho, H. L. So, S. K. Lam, et al. 2006. Effects of cyclooxygenase-1 and -2 gene disruption on Helicobacter pylori-induced gastric inflammation. J. Infect. Dis. 193: 1037-1046.
18. Thulin, P., L. Johansson, D. E. Low, B. S. Gan, M. Kotb, A. McGeer, and A. Norrby-Teglund. 2006. Viable group A streptococci in macrophages during acute soft tissue infection. PLoS Med. 3: e53.
19. Goldmann, O., G. S. Chhatwal, and E. Medina. 2003. Immune mechanisms underlying host susceptibility to infection with group A streptococci. J. Infect. Dis. 187: 854-861.
20. Goldmann, O., M. von Köckritz-Blickwede, C. Höltje, G. S. Chhatwal, R. Geffers, and E. Medina. 2007. Transcriptome analysis of murine macrophages in response to infection with Streptococcus pyogenes reveals an unusual activation program. Infect. Immun. 75: 4148-4157.
21. Hwang, D. 1989. Essential fatty acids and immune response. FASEB J. 3: 2052-2061. (Pubitemid 19187614)
22. Lee, S. H., E. Soyoola, P. Chanmugam, S. Hart, W. Sun, H. Zhong, S. Liou, D. Simmons, and D. Hwang. 1992. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J. Biol. Chem. 267: 25934-25938.
23. Luca-Harari, B., J. Darenberg, S. Neal, T. Siljander, L. Strakova, A. Tanna, R. Creti, K. Ekelund, M. Koliou, P. T. Tassios, et al; Strep-EURO Study Group. 2009. Clinical and microbiological characteristics of severe Streptococcus pyogenes disease in Europe. J. Clin. Microbiol. 47: 1155-1165.
24. Norrby-Teglund, A., S. Chatellier, D. E. Low, A. McGeer, K. Green, and M. Kotb. 2000. Host variation in cytokine responses to superantigens determine the severity of invasive group A streptococcal infection. Eur. J. Immunol. 30: 3247-3255.
25. Tilley, S. L., T. M. Coffman, and B. H. Koller. 2001. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J. Clin. Invest. 108: 15-23.
26. Bhagwat, S. S., P. R. Hamann, W. C. Still, S. Bunting, and F. A. Fitzpatrick. 1985. Synthesis and structure of the platelet aggregation factor thromboxane A2. Nature 315: 511-513.
27. Goldmann, O., M. Rohde, G. S. Chhatwal, and E. Medina. 2004. Role of macrophages in host resistance to group A streptococci. Infect. Immun. 72: 2956-2963.
28. Aronoff, D. M., C. Canetti, C. H. Serezani, M. Luo, and M. Peters-Golden. 2005. Cutting edge: macrophage inhibition by cyclic AMP (cAMP): differential roles of protein kinase A and exchange protein directly activated by cAMP-1. J. Immunol. 174: 595-599.
29. Ballinger, M. N., D. M. Aronoff, T. R. McMillan, K. R. Cooke, K. Olkiewicz, G. B. Toews, M. Peters-Golden, and B. B. Moore. 2006. Critical role of prostaglandin E2 overproduction in impaired pulmonary host response following bone marrow transplantation. J. Immunol. 177: 5499-5508.
30. Breyer, R. M., C. K. Bagdassarian, S. A. Myers, and M. D. Breyer. 2001. Prostanoid receptors: subtypes and signaling. Annu. Rev. Pharmacol. Toxicol. 41: 661-690.
31. Narumiya, S., Y. Sugimoto, and F. Ushikubi. 1999. Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 79: 1193-1226.
32. Hata, A. N., and R. M. Breyer. 2004. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol. Ther. 103: 147-166.
33. Serezani, C. H., J. Chung, M. N. Ballinger, B. B. Moore, D. M. Aronoff, and M. Peters-Golden. 2007. Prostaglandin E2 suppresses bacterial killing in alveolar macrophages by inhibiting NADPH oxidase. Am. J. Respir. Cell Mol. Biol. 37: 562-570.
34. Kopperud, R., C. Krakstad, F. Selheim, and S. O. Døskeland. 2003. cAMP effector mechanisms. Novel twists for an 'old' signaling system. FEBS Lett. 546: 121-126.
35. Farrell, J. P., and C. E. Kirkpatrick. 1987. Experimental cutaneous leishmaniasis. II. A possible role for prostaglandins in exacerbation of disease in Leishmania major-infected BALB/c mice. J. Immunol. 138: 902-907.
36. Short, B. L., M. K. Miller, and J. Pan. 1988. Group B streptococcal (GBSS) newborn septic shock model: the role of prostaglandins. Prog. Clin. Biol. Res. 264: 333-336.
37. Aronoff, D. M., Y. Hao, J. Chung, N. Coleman, C. Lewis, C. M. Peres, C. H. Serezani, G. H. Chen, N. Flamand, T. G. Brock, and M. Peters-Golden. 2008. Misoprostol impairs female reproductive tract innate immunity against Clostridium sordellii. J. Immunol. 180: 8222-8230.
38. Aronoff, D. M., C. Canetti, and M. Peters-Golden. 2004. Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. J. Immunol. 173: 559-565.
39. Mancuso, P., T. J. Standiford, T. Marshall, and M. Peters-Golden. 1998. 5-Lipoxygenase reaction products modulate alveolar macrophage phagocytosis of Klebsiella pneumoniae. Infect. Immun. 66: 5140-5146.
40. Schmid, A., K. H. Thierauch, W. D. Schleuning, and H. Dinter. 1995. Splice variants of the human EP3 receptor for prostaglandin E2. Eur. J. Biochem. 228: 23-30.
41. Serezani, C. H., M. N. Ballinger, D. M. Aronoff, and M. Peters-Golden. 2008. Cyclic AMP: master regulator of innate immune cell function. Am. J. Respir. Cell Mol. Biol. 39: 127-132.
42. Aronoff, D. M., C. Lewis, C. H. Serezani, K. A. Eaton, D. Goel, J. C. Phipps, M. Peters-Golden, and P. Mancuso. 2009. E-prostanoid 3 receptor deletion improves pulmonary host defense and protects mice from death in severe Streptococcus pneumoniae infection. J. Immunol. 183: 2642-2649.
43. Kotb, M., A. Norrby-Teglund, A. McGeer, H. El-Sherbini, M. T. Dorak, A. Khurshid, K. Green, J. Peeples, J. Wade, G. Thomson, et al. 2002. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat. Med. 8: 1398-1404.
44. Medina, E., O. Goldmann, M. Rohde, A. Lengeling, G. S. Chhatwal, and G. S. Chhatwals. 2001. Genetic control of susceptibility to group A streptococcal infection in mice. J. Infect. Dis. 184: 846-852.
45. Rimailho, A., B. Riou, C. Richard, and P. Auzepy. 1987. Fulminant necrotizing fasciitis and nonsteroidal anti-inflammatory drugs. J. Infect. Dis. 155: 143-146.
46. Aronoff, D. M., and K. C. Bloch. 2003. Assessing the relationship between the use of nonsteroidal antiinflammatory drugs and necrotizing fasciitis caused by group A streptococcus. Medicine (Baltimore) 82: 225-235.
47. Peters-Golden, M., and W. R. Henderson, Jr. 2007. Leukotrienes. N. Engl. J. Med. 357: 1841-1854.
48. Serhan, C. N., N. Chiang, and T. E. Van Dyke. 2008. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8: 349-361.